Shots:
- Makana Therapeutics has collaborated with Tonix Pharmaceuticals for TNX-1500 (anti-CD40L mAb) to reduce rejection of Makana’s genetically engineered (GE) pig organs in xenotransplantation
- Preclinical R&D collaboration may extend across Makana’s kidney, heart, & islet cell transplant programs, with an aim to support the US FDA’s IND submission for compassionate use in xenotransplantation pts
- Makana’s genetically engineered pigs have deleted swine leukocyte antigen (SLA) & has demonstrated improved human compatibility along with high fertility & birthing rates to improve global organ supply potential
Ref: Globenewswire | Image: Tonix Pharmaceuticals & Makana Therapeutics
Related News:- Tonix Pharmaceuticals Reports the US FDA’s NDA Acceptance of TNX-102 SL for Treating Fibromyalgia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
